<DOC>
	<DOC>NCT00255281</DOC>
	<brief_summary>The current study is designed to assess the efficacy and safety of iv AZD7009 in conversion from AF</brief_summary>
	<brief_title>Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Clinical indication for cardioversion of Atrial Fibrillation. Effective oral anticoagulation according to local routines or a TEE without any finding of intracardial thrombus or signs of thrombogenecity Clinically significant sinus and/or AV node dysfunction. Serum or plasma potassium &lt;3.8 mmol/L or &gt;5.0 mmol/L. QTc(Bazett) &gt;450 ms. Any QRS duration &gt;150 ms</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>